Let us discuss how some of its key drugs performed in the quarter So far this year, Amgen’s stock has risen 8.8% against the industry‘s 1.4% decline. In general medicine, Repatha is Amgen’s ...

Fresh off earning FDA approval for a prefilled syringe version of Vyvgart Hytrulo for at-home administration, argenx is building buzz with a new direct-to-consumer campaign. The “Treatment MY ...

with management highlighting differentiated profiles for MariTide and Repatha as mitigating factors. Amgen’s Q1 2025 earnings call highlighted strong revenue and volume growth, driven by key ...

We recently published a list of The Best and Worst Dow Stocks. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other Dow stocks. The Dow Jones ...

Fourteen products, including Repatha, Blincyto, Tezspire, Tavneos and Evenity, achieved double-digit volume growth in the quarter. Let us discuss how some of its key drugs performed in the quarter So ...

Amgen is a leader in biotechnology-based human ... Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon ...

Amgen’s next-generation cholesterol drug has shown it can reverse the build up of plaque build-up in coronary arteries which can lead to a heart attack or stroke. The company’s Repatha ...

Investors with a lot of money to spend have taken a bearish stance on Amgen AMGN. And retail traders ... Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras ...

Amgen's diversified portfolio ensures steady revenue but modest growth, with no single drug contributing more than 15% to total revenue. Recent revenue growth and margin upticks are promising, but ...

Amgen's cholesterol-lowering antibody Repatha is being launched in Europe at well below the new drug's cost in the US, raising the chance that American payers will seek hefty discounts on the drug.